Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Alumis Inc. | ESK-001 - (LUMUS) | Systemic Lupus Erythematosus (SLE) | Phase 2b | Enrollment Conclusion | Oral | Immunology |
| Alumis Inc. | Izokibep | Psoriatic arthritis (PsA) | Phase 2/3 | Data Released | Subcutaneous | Immunology: Anti-TNF |
| Alumis Inc. | ESK-001 - (ONWARD3) | Moderate-to-severe plaque psoriasis | Phase 3 | Enrollment Initiation | oral | Immunology: Anti-TNF |
| Alumis Inc. | Subcutaneous lonigutamab - (LONGITUDE) | Thyroid eye disease (TED) | Phase 3 | Trial Planned | Subcutaneous | Opthalmic |
| Alumis Inc. | Envudeucitinib (ESK-001) - (ONWARD1) | Moderate-to-severe plaque psoriasis | Phase 3 | Data Released | Oral | Immunology: Anti-TNF |
| Alumis Inc. | izokibep | Non-infectious, non-anterior uveitis | Phase 2/3 | Data Released | Subcutaneous | Opthalmic |
| Alvotech | AVT16 - (Entyvio biosimilar) | Severe active Ulcerative Colitis | Phase 3 | Enrollment Initiation | Intravenous | Gastroenterology |
| Alvotech | AVT06 - (EYLEA biosimilar) | Eye disorders | BLA Filing | Data Released | Intravitreal injection | Opthalmic |
